Variables | Luminal A (N = 497) | Luminal B (N = 123) | Her2-enriched (N = 174) | TNBC (N = 287) | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
OR | 95%CI | P value | OR | 95%CI | P value | OR | 95%CI | P value | OR | 95%CI | P value | |
DM or glucose intolerance | 1.054 | 0.680–1.632 | 0.815 | 5.697 | 2.278–14.248 | < 0.001 | 2.004 | 0.967–4.149 | 0.061 | 1.022 | 0.434–2.405 | 0.961 |
Dyslipidemia | 0.837 | 0.543–1.291 | 0.422 | 1.548 | 0.644–3.723 | 0.329 | 1.068 | 0.483–2.360 | 0.871 | 1.204 | 0.635–2.282 | 0.569 |
Hypertension | 0.782 | 0.522–1.172 | 0.234 | 1.791 | 0.759–4.229 | 0.183 | 1.111 | 0.561–2.202 | 0.763 | 0.972 | 0.563–1.679 | 0.919 |
BMI risk (> 27.7) | 1.145 | 0.730–1.798 | 0.514 | 1.410 | 0.544–3.653 | 0.480 | 0.730 | 0.293–1.820 | 0.499 | 0.795 | 0.416–1.520 | 0.488 |
DM/glucose intolerance + Dyslipidemia | 1.227 | 0.732–2.058 | 0.438 | 9.100 | 2.495–33.196 | 0.001 | 1.513 | 0.569–4.026 | 0.407 | 1.675 | 0.758–3.705 | 0.202 |
DM/glucose intolerance + Hypertension | 1.069 | 0.670–1.704 | 0.781 | 5.467 | 2.124–14.072 | < 0.001 | 2.304 | 1.071–4.959 | 0.033 | 1.187 | 0.618–2.281 | 0.607 |
Dyslipidemia + Hypertension | 0.893 | 0.613–1.378 | 0.613 | 1.812 | 0.748–4.391 | 0.188 | 1.167 | 0.525–2.593 | 0.705 | 1.150 | 0.600–2.206 | 0.672 |
Dyslipidemia + BMI risk | 1.002 | 0.568–1.766 | 0.995 | 0.916 | 0.237–3.543 | 0.899 | 1.245 | 0.308–5.034 | 0.759 | 0.855 | 0.350–2.089 | 0.730 |
Hypertension + BMI risk | 1.001 | 0.598–1.677 | 0.997 | 1.258 | 0.410–3.860 | 0.688 | 1.027 | 0.348–3.032 | 0.962 | 1.000 | 0.474–2.109 | 1.000 |
DM/glucose intolerance + BMI risk | 1.076 | 0.549–2.108 | 0.831 | 2.359 | 0.374–14.874 | 0.361 | 0.811 | 0.162–4.053 | 0.798 | 1.099 | 0.410–2.942 | 0.852 |
≥3 metabolic comorbidities | 1.330 | 0.850–2.082 | 0.212 | 5.014 | 1.969–12.767 | 0.001 | 1.447 | 0.602–3.482 | 0.409 | 1.576 | 0.817–3.040 | 0.175 |
Any metabolic comorbidity | 0.833 | 0.556–1.247 | 0.374 | 2.554 | 0.948–6.879 | 0.064 | 0.905 | 0.458–1.788 | 0.773 | 0.794 | 0.469–1.344 | 0.391 |